•
Nov 22, 2024
Nov 18, 2024
Nov 12, 2024
Nov 21, 2024
Nov 20, 2024
Nov 8, 2024
Nov 7, 2024
Nov 6, 2024
Altimmune, Inc. [ALT] has reported fiscal Q1 loss of $20.10 million.
On a per-share basis, the DE based company said its diluted earnings are $0.40.
The Pharmaceutical Preparations firm posted revenue of $0.21 million in this period.
Also Read: Altimmune Announces First Quarter 2023 Financial Results and Provides a Business UpdateAltimmune to Participate at Two Upcoming Investor ConferencesAltimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for ...Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of DirectorsAltimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM ...